Did you miss "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.

Image placeholder title

In an "Executive Decision" segment, Cramer spoke with Richard Pops, chairman and CEO of Alkermes (ALKS) - Get Report . Earlier today, Pops said that 2018 will be a transformative year for his company.

Pops explained that in biotech, it can take 10 years and a billion dollars to develop a drug. Some years, you work with apparently nothing to show for it, but other years the data come in and the world can see your progress. He said 2018 will be the latter type of year for all of their programs.

On the opioid addiction front, Pops said that Vivitrol is growing beautifully and now that more data is being released on the drug's effectiveness, Vivitrol's best days are clearly ahead of it.

Meanwhile, Alkermes' drug for schizophrenia, currently known as "3831," is in Phase III testing and has shown an ability to block the weight gain associated with current treatment efforts. How a drug works is only part of the equation, Pops said, and if a patient gains 50 pounds on a drug, they won't take it. That's part of the reason more than half of all schizophrenia patients don't stay on their medication.

Cramer and the AAP team talk about Nvidia (NVDA) - Get Report , Intel (INTC) - Get Report , Alphabet (GOOGL) - Get Report and more. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

Over on Real Money, Cramer says cryptocurrencies, marijuana and Micron (MU) - Get Report are hot speculator plays. Get more on his insights with a free trial subscription to Real Money.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To read a full recap of this episode of "Mad Money," click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

More of What's Trending on TheStreet:

At the time of publication, Cramer's Action Alerts PLUS had a position in NVDA, GOOGL.